Oncofid-P-B: a novel treatment for BCG unresponsive carcinoma in situ (CIS) of the bladder: Results of a prospective European Multicentre study at 15 months from treatment start.

Autor: Hurle R; Department of Urology, IRCCS Humanitas Research Hospital, via Manzoni 56, 20089, Rozzano, Italy; Department of Biomedical Sciences, Humanitas University, via Rita Levi Montalcini 4, 20090 Pieve Emanuele, Milan, Italy. Electronic address: rodolfo.hurle@humanitas.it., Guazzoni G; Department of Biomedical Sciences, Humanitas University, via Rita Levi Montalcini 4, 20090 Pieve Emanuele, Milan, Italy., Colombo P; Department of Pathology, Humanitas Research Hospital IRCCS, Rozzano, Italy., Santoro A; Department of Oncology, Humanitas Research Hospital IRCCS, Rozzano, Italy., De Cobelli O; Department of Urology, IEO, European Institute of Oncology IRCCS, Milan, Italy., Trapani ED; Department of Urology, IEO, European Institute of Oncology IRCCS, Milan, Italy., Nohales G; Department of Urology, Hospital del Mar, Barcelona, Spain., Carlos L; Department of Urology, Hospital Universitario Fundacion Alcorcon, Madrid, Spain., Duran-Merino R; Department of Urology, H.G.U. 'Gregorio Marañón', Madrid, Spain., Lazzeri M; Department of Urology, IRCCS Humanitas Research Hospital, via Manzoni 56, 20089, Rozzano, Italy.
Jazyk: angličtina
Zdroj: Urologic oncology [Urol Oncol] 2022 Jan; Vol. 40 (1), pp. 11.e9-11.e15. Date of Electronic Publication: 2021 Oct 12.
DOI: 10.1016/j.urolonc.2021.07.007
Abstrakt: Purpose: This study reports the safety and efficacy of Oncofid - P-B, a novel compound under development by Fidia Farmaceutici S.p.A. with specific binding to CD44 receptor, in patients with CIS unresponsive or intolerant to BCG.
Materials and Methods: This is a phase 1 open-label, single arm, multicenter European study to assess safety, tolerability and efficacy of Oncofid-P-B administered in 20 patients with CIS ± Ta-T1, unresponsive or intolerant to BCG, unwilling or unfit for cystectomy. Oncofid-P-B was administered by intravesical instillation for 12 consecutive weeks (intensive phase) followed, in CR patients, by 12 monthly instillations (maintenance phase). The primary objective was the overall safety profile. Secondary objectives included: i) any evidence of antitumor activity, ii) patient's compliance, iii) systemic absorption. The CR was defined as a negative cystoscopy, negative biopsy of the urothelium and negative cytology.
Results: At the end of the intensive phase, 15 of the 20 enrolled patients (75%), achieved the CR. Patients still in CR after 3, 6, 9 and 12 months of maintenance phase were 13 (65%), 12 (60%), 9 (45%) and 8 (40%), respectively. Only seven (5 mild and 2 moderate) drug-related AEs were reported in three patients. No drug related serious AEs and no drug related withdrawals have been reported. In all plasma samples, the drug concentratiosn was below the LLOQ (1ng/ml).
Conclusions: Oncofid-P-B is very safe, well tolerated and highly effective (75% CR) when administered weekly for up to 12 consecutive weeks (75% CR), with 40% CR still after 15 months from treatment start.
(Copyright © 2021. Published by Elsevier Inc.)
Databáze: MEDLINE
Externí odkaz: